XPO1 and hematologic disorder: Especially, clinical trials using XPO1 inhibitors in hematologic malignancies are being investigated in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) protocol, as well as targeted agents such as ibrutinib, or has been combined with corticosteroid and/or bortezomib [11,20].